Adaptive acquisition functions (UCB-guided Bayesian optimization) will reduce the number of experimental trials required to identify coalition-stable drug synergy pairs by ≥40% compared to fixed EI acquisition, when applied to residual graph isomorphism networks trained on MSH3-KPC-3 interaction graphs.
Adaptive acquisition functions (UCB-guided Bayesian optimization) will reduce the number of experimental trials required to identify coalition-stable drug synergy pairs by ≥40% compared to fixed EI acquisition, when applied to residual graph isomorphism networks trained on MSH3-KPC-3 interaction graphs.
Adversarial Debate Score
53% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- Drug Synergy Prediction via Residual Graph Isomorphism Networks and Attention Mechanisms
In the treatment of complex diseases, treatment regimens using a single drug often yield limited efficacy and can lead to drug resistance. In contrast, combination drug therapies can significantly imp...
- Improving search efficiency via adaptive acquisition function selection in discrete black-box optimization
In discrete-variable black-box optimization, the number of candidate solutions grows combinatorially, while each evaluation is often expensive. Therefore, it is important to identify promising solutio...
- Pharmacology Knowledge Graphs: Do We Need Chemical Structure for Drug Repurposing?
The contributions of model complexity, data volume, and feature modalities to knowledge graph-based drug repurposing remain poorly quantified under rigorous temporal validation. We constructed a pharm...
- Asymmetric Focal Loss Improves Graph Neural Network Prediction of Drug-Drug Interactions
Background: Graph neural networks improve computational prediction of polypharmacy side effects, but standard binary cross-entropy training allocates equal capacity to well-classified and difficult ex...
Computational Result
An LLM's reading of the literature — not computational verification.
Adaptive methods may improve efficiency, but evidence is mixed.
Method: literature_meta · Result: inconclusive · Confidence: 60%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
When a residual graph isomorphism network (R-GIN) trained on MSH3–KPC-3 protein-protein/drug interaction graphs is used as a surrogate model for Bayesian optimization over a drug-pair combination space, an Upper Confidence Bound (UCB) acquisition function will identify all coalition-stable drug synergy pairs (defined as pairs whose Shapley-value-derived synergy score exceeds a fixed threshold τ and remains stable under leave-one-out perturbation of the coalition) using ≥40% fewer labeled experimental trials (oracle queries) than a fixed-parameter Expected Improvement (EI) acquisition function, measured as the number of queries needed to reach 95% recall of the true stable-pair set, averaged over ≥30 independent runs with different random seeds and initial designs, at statistical significance p<0.05 (paired Wilcoxon signed-rank test) and effect size Cohen's d≥0.5.
- If mean trial reduction is <40% (or negative, i.e., UCB requires more trials than EI) across ≥30 seeds, hypothesis is disproven.
- If the 95% CI on trial-reduction crosses zero or the paired significance test yields p≥0.05, hypothesis is disproven.
- If UCB's advantage disappears (|Δ|<10%) when surrogate calibration is controlled for (ablation), the causal claim (adaptive acquisition specifically, not surrogate quality) is disproven.
- If results fail to replicate on a second independent interaction-graph dataset (e.g., synthetic benchmark or a second real dataset) with the same direction and magnitude (within 15 percentage points), external validity is disproven.
Spine & Adversarial Read
- highThe comparison uses a frozen offline oracle (pre-labeled ground truth) rather than real wet-lab feedback, so the result may not transfer to true prospective experimental campaigns where noise, batch effects, and assay variability are present.Partially addressed by pre-registering a synthetic-benchmark replication arm and noting the stationarity assumption in boundary conditions, but the EVP does not include a live/semi-live wet-lab validation phase — this is an acknowledged gap requiring a follow-up in-vitro confirmation study before real deployment claims can be made.
- highWhy R-GIN specifically and not simpler GNN variants (plain GCN, GAT) or non-graph surrogates (random forest on molecular descriptors)? The choice of surrogate architecture is not justified against alternatives, so any observed acquisition-function effect could be confounded with an unjustified architecture choice.Not resolved in current design — the EVP should add a surrogate-architecture ablation (GCN, GAT, R-GIN, RF baseline) crossed with both acquisition functions to confirm the UCB-vs-EI effect is robust across surrogate choice, not an artifact of R-GIN's specific inductive bias. This is a methodology justification gap that should be closed before publication.
- mediumThe 'coalition-stability' construct (Shapley value + leave-one-out variance) is a nonstandard and somewhat ad hoc operationalization of drug synergy; a skeptic could argue this definition was chosen post hoc to make the problem tractable for game-theoretic framing rather than reflecting established pharmacological synergy criteria (e.g., Bliss independence, Loewe additivity).Partially addressed by cross-referencing with standard Bliss/Loewe synergy scores from DrugComb/NCI-ALMANAC as the labeling source, but the mapping from those standard scores to the Shapley-based 'coalition stability' label needs explicit validation (e.g., correlation between Shapley-stability labels and Bliss-synergy labels) — not currently included as a reported diagnostic.
Experimental Protocol
Minimum viable test (MVT): simulate a closed-loop BO campaign against a frozen "oracle" — the fully trained R-GIN surrogate evaluated on held-out ground-truth synergy labels — with two acquisition functions (UCB vs EI) competing to find all coalition-stable pairs from a fixed candidate pool of ~1,000 drug pairs derived from MSH3-KPC-3 interaction data. Each acquisition function runs 30 independent trials (different random seeds, different initial 10-point Latin hypercube designs). Track cumulative queries to reach 95% recall of ground-truth stable set. Compare query-count distributions.
- Primary: MSH3-KPC-3 interaction graph dataset (protein-protein interaction + drug-target bipartite graph); if not already curated, construct from STRING/BioGRID + DrugBank/DGIdb cross-reference, minimum 1,000 nodes, 5,000 edges.
- Ground-truth synergy labels: existing combination screening dataset (e.g., DrugComb, NCI-ALMANAC, or O'Neil et al. dataset) mapped onto MSH3/KPC-3-adjacent pathway pairs; need ≥200 labeled drug pairs with measured synergy (Bliss/Loewe scores) to serve as oracle ground truth.
- Synthetic validation set: a second, independently generated synthetic graph-synergy benchmark (e.g., using a graph generative model) to test generalization, ≥500 pairs.
- Model artifact: pretrained R-GIN (residual GIN, 4–6 layers, hidden dim 128–256) — must be trained and validated (AUROC≥0.75 on held-out synergy prediction) BEFORE BO experiments begin.
- Software: BoTorch/GPyTorch or Ax for BO loop; PyTorch Geometric for R-GIN; a Shapley-value coalition-stability module (custom, using approximate Shapley via Monte Carlo sampling, 1,000 permutations per evaluation).
- Primary: mean trial reduction ≥40% (UCB vs EI), 95% CI lower bound >30%, p<0.05 (Wilcoxon), Cohen's d≥0.5, replicated in synthetic benchmark with reduction ≥25%.
- Secondary: UCB's advantage persists (≥25% reduction) in retrained-surrogate ablation arm, confirming effect isn't purely a frozen-surrogate artifact.
- Calibration check: R-GIN ECE <0.1 on held-out data (precondition for interpretable result).
- Mean reduction <40% OR CI includes zero OR p≥0.05 → hypothesis fails as stated (may still show weaker directional effect worth reporting).
- No significant difference between UCB and EI on synthetic benchmark → generalization fails.
- Advantage disappears when surrogate is untrained/random → effect attributable to surrogate not acquisition function, hypothesis as causally stated fails.
- High variance (CV>75%) in query-count distributions across seeds → result deemed unreliable regardless of mean.
ROI Projection
Implementation Sketch
# Phase 1: Surrogate training graph = build_MSH3_KPC3_interaction_graph(sources=[STRING, DrugBank]) model = ResidualGIN(layers=5, hidden=256, dropout=0.2) train(model, labeled_pairs_70pct, epochs=200, early_stop_patience=15) assert calibration_ECE(model, held_out_30pct) < 0.10 assert AUROC(model, held_out_30pct) >= 0.75 # Phase 2: Ground truth coalition-stability labeling for pair in candidate_pool: shapley_score = monte_carlo_shapley(pair, coalition_graph, n_perm=1000) stability = leave_one_out_variance(pair, coalition_graph) < 0.10 * shapley_score ground_truth[pair] = (shapley_score > tau) and stability # Phase 3: BO loop (per acquisition function, per seed) def bo_loop(acq_fn, seed, pool, ground_truth, budget=300): rng = seed_rng(seed) observed = latin_hypercube_init(pool, n=10, rng=rng) gp = fit_GP_on_embeddings(model.embed(observed)) queries = 10 while recall(observed, ground_truth) < 0.95 and queries < budget: next_pair = acq_fn.select(gp, pool - observed) # UCB: mu + beta*sigma label = ground_truth[next_pair] # oracle reveal observed.add((next_pair, label)) gp = fit_GP_on_embeddings(model.embed(observed)) # or update posterior queries += 1 return queries results_UCB = [bo_loop(UCB(beta=2), s, pool, gt) for s in range(30)] results_EI = [bo_loop(EI(), s, pool, gt) for s in range(30)] reduction_pct = 100 * (mean(results_EI) - mean(results_UCB)) / mean(results_EI) wilcoxon_test(results_UCB, results_EI)
- After Phase 1 (surrogate training): if AUROC<0.70 or ECE>0.15, abort and revisit graph construction/model architecture before proceeding (est. cost saved: ~80% of full budget).
- After 10 pilot BO trials per arm (before full 30-seed run): if observed reduction is <15% or variance is extremely high (CV>100%), abort or redesign acquisition parameters before committing to full 30-seed statistical run.
- After ablation arm (randomized surrogate): if UCB advantage persists identically with untrained surrogate, abort interpretation as "adaptive acquisition + good surrogate" and re-scope claim.
- Mid-campaign data audit at 50% of planned trials: verify ground-truth labels haven't drifted/been mis-scored; if error rate >5% found, pause and re-validate labels before continuing.
NAMED_EXPERTS: []
CLOSEST_EXISTING_WORK: []
NOVELTY_NARROWING_REQUIRED: false
SPINE_STATEMENT: This hypothesis tests whether UCB acquisition in Bayesian optimization over an R-GIN surrogate reduces the number of experimental trials needed to identify coalition-stable drug synergy pairs by at least 40% compared to fixed EI acquisition.